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The present study was undertaken to test whether
inhibition of the proangiogenic inflammatory cyto-
kine tumor necrosis factor (TNF)- can modulate ret-
inal hypoxia and preretinal neovascularization in a
murine model of oxygen-induced retinopathy (OIR).
OIR was produced in TNF-/ and wild-type (WT)
control C57B6 neonatal mice by exposure to 75%
oxygen between postnatal days 7 and 12 (P7 to P12).
Half of each WT litter was treated with the cytokine
inhibitor semapimod (formerly known as CNI-1493)
(5 mg/kg) by daily intraperitoneal injection from the
time of reintroduction to room air at P12 until P17.
The extent of preretinal neovascularization and in-
traretinal revascularization was quantified by image
analysis of retinal flat-mounts and retinal hypoxia
correlated with vascularization by immunofluores-
cent localization of the hypoxia-sensitive drug pi-
monidazole (hypoxyprobe, HP). HP adducts were
also characterized by Western analysis and quantified
by competitive enzyme-linked immunosorbent assay.
TNF-/ and WT mice showed a similar sensitivity
to hyperoxia-induced retinal ischemia at P12. At P13
some delay in early reperfusion was evident in TNF-
/ and WT mice treated with semapimod. How-
ever, at P17 both these groups had significantly better
vascular recovery with less ischemic/hypoxic retina
and preretinal neovascularization compared to un-
treated retinopathy in WT mice. Immunohistochem-
istry showed deposition of HP in the avascular inner
retina but not in areas underlying preretinal neovas-
cularization, indicating that such aberrant vascula-
ture can reduce retinal hypoxia. Inhibition of TNF-
significantly improves vascular recovery within isch-
emic tissue and reduces pathological neovasculariza-
tion in OIR. HP provides a useful tool for mapping
and quantifying tissue hypoxia in experimental isch-
emic retinopathy. (Am J Pathol 2005, 166:637–644)
Angiogenesis is associated with two major paradigms of
causation: inflammation and hypoxia. Although the cen-
tral players, such as vascular endothelial growth factor
(VEGF), are common to each of these models,1,2 it is
clear that some molecules characteristically associated
with angiogenesis in either hypoxia or inflammation may
be important to both in certain circumstances. In partic-
ular, the roles of the inflammatory cytokines, especially
tumor necrosis factor (TNF)-, interleukin (IL)-1, and IL-8,
are emphasized in inflammation-associated angiogene-
sis3–7 although their importance in noninflammatory an-
giogenesis is also becoming evident.8 There is also con-
siderable evidence that hypoxia-inducible factor, the
chief trans-acting transcription factor for VEGF may rep-
resent an important link between angiogenesis occurring
during hypoxia or in inflammation.9,10 In addition to hypoxia,
hypoxia-inducible factor has been shown to be regulated
by cytokines, even under normoxic conditions.11
Oxygen-induced retinopathy (OIR) in neonatal mice12
represents a model of hypoxia-driven retinal neovascu-
larization devoid of any obvious inflammatory infiltrate. In
this model the mice are exposed to hyperoxia for 5 days
between postnatal day 7 (P7) and P12. As vascularization
of the murine retina takes place throughout the first 2
weeks of postnatal development, the retinal vasculature
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at P7 is immature with only the primary inner vascular
plexus in place. The hyperoxia causes vaso-obliteration
of the central retinal capillary beds by two recognized
mechanisms: it rapidly down-regulates VEGF production
by the retinal parenchyma and renders the immature
capillaries vulnerable to apoptosis13–15 while simulta-
neously inducing an oxidative insult mediated by endog-
enous nitric oxide production.16 It is also likely that the
oxidative insult is augmented by up-regulation of pigment
epithelium-derived factor, which has been shown to be
anti-angiogenic and proapoptotic for activated vascular
endothelial cells.17–19 After return to room air at P12 the
avascular regions of the central retina are rendered hy-
poxic with an associated liberation of angiogenic growth
factors.20 Subsequently, retinal angiogenesis occurs in
two separate locations. Firstly, there is a variable revas-
cularization of the ischemic central capillary beds. Sec-
ondly, preretinal neovascularization results in the prolif-
eration of new vessels on the surface of the retina, within
the vitreous body. The preretinal vessels are derived from
viable vasculature at the margins of the ischemic central
retina, from the perfused periphery and the optic disk.
Neovascular complexes tend to overlie persistently isch-
emic areas of the central retina and are less developed in
quadrants where intraretinal revascularization has oc-
curred. This report describes how alteration of the cyto-
kine profile during the hypoxic/angiogenic phase of OIR
by semapimod (formerly known as CNI-1493), a transla-
tional inhibitor of TNF-,21,22 or by ablation of the TNF-
gene may alter the balance of hypoxia and angiogenesis
within the intraretinal and preretinal compartments of the
eye. It also indicates fundamental differences in the
needs of angiogenic vessels proliferating within differing
extracellular environments.
Materials and Methods
Experimental Design
OIR was induced in C57/BL6 wild-type (WT) and TNF-
/ mice23 (on a C57/BL6 genetic background) (Ban-
ton & Kingman, Hull, UK) as described by Smith and
colleagues.12 Briefly, neonatal mice and their nursing
dams were exposed to 75% oxygen (PRO-OX 110 cham-
ber oxygen controller used; Biospherix Ltd., Redfield,
NY) between postnatal day 7 (P7) and P12 producing
vaso-obliteration and cessation of vascular development
in the capillary beds of the central retina. Return of the
animals to room air at P12 renders the central retina
ischemic and hypoxic, and results in preretinal neovas-
cularization between P15 and P21 with maximal neovas-
cularization at P17. In each experiment two P12 animals
received an intravenous injection of fluorescein-dextran
(2  106 MW) (Sigma-Aldrich Ltd., Gillingham, UK) and
were sacrificed immediately on return to room air. Retinal
flat-mount angiograms were then prepared to confirm
consistent vaso-obliteration of the central capillary
beds. As the C57/BL6 dams showed inconsistent care
and nutrition of the pups when returned to room air, at
P12 all C57/BL6 and TNF-/ pups were cross-fos-
tered to nursing Swiss dams that had not been ex-
posed to hyperoxia.
Assessment of Preretinal Neovascularization
and Intraretinal Angiogenesis
Multiple timed matings were prepared for both WT and
TNF-/ mice and subjected to OIR. WT neonates
were divided into two equal groups; one being treated
with semapimod (Cytokine PharmaSciences, Inc., King of
Prussia, PA) (5 mg/kg) by daily intraperitoneal injection
between P12 and P17 and the other OIR control group
treated with vehicle (2.5% mannitol in water) alone. In all
cases there was a minimum of 10 pups/group. At P17,
semapimod-treated mice, controls, and TNF-/ mice
previously exposed to hyperoxia were terminally anesthe-
tized and perfused with fluorescein-dextran via the left
ventricle. On enucleation, both eyes were fixed in 4%
paraformaldehyde for 4 hours at 4°C, one for subsequent
wax histology and the other for flat-mount angiography or
fluorescent lectin histochemical staining with Griffonia
simplicifolia isolectin B4 (Figure 1). Each experiment was
conducted three times.
Configuration of the microvascular tree was assessed
in retinal flat-mounts using an image analysis-based eval-
uation of 1) avascular regions, 2) areas of intraretinal
perfusion, and 3) preretinal neovascularization (Figure 1).
Whole retinas fluorescently stained with biotin-labeled
isolectin B4 and Alexa-488 streptavidin (described below
and illustrated in Figure 1) were analyzed in a blinded
Figure 1. Grading of microvascular configuration in OIR. The retinal micro-
vasculature was localized and identified in retinal flat-mounts using confocal
scanning laser microscopy. This representative image shows area of normal
intraretinal capillaries (Nor), regions of avascular retina (ischemia, AV), and
distinct, hyperfluorescent regions of preretinal neovascularization (Neo).
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manner by a skilled investigator using the Lucia image
analysis system (supplied by Nikon, UK). The three cat-
egories described above were outlined and quantified in
each quadrant of the retina as fractions of the total area of
retina analyzed. Images were acquired using a Nikon
Eclipse E400 fluorescence microscope at 40 magnifi-
cation using a Nikon DXM 1200 digital camera via Nikon
image-capture software (at 600 dpi resolution) and
stored as TIFF files. Five separate fields were required to
cover the four retinal quadrants and the optic disk within
each flat-mount. The files were opened in LUCIA G (ver-
sion 4.71) image analysis software (obtained from Nikon),
which allows pixel calibration in m for each microscope
lens magnification. A binary overlay was prepared from
each image and total retinal areas, in m2, were as-
sessed by interactively drawing a line around the edge of
individual retinal quadrants. Ischemic (nonvascularized)
or neovascularized areas were similarly outlined and their
area fractions of the total retinal area in each image
calculated by the software. Often the greater fluorescent
intensity of the neovascular tissue could be outlined and
assessed completely automatically by setting a suitable
threshold of image intensity for capture in the binary
image, sufficient to outline only the neovascular tufts.
Statistical analysis was performed using a one-way
analysis of variance and a Tukey-Kramer post test for
multiple comparisons; a P value 0.05 was considered
significant.
Sodium Dodecyl Sulfate-Polyacrylamide Gel
Electrophoresis and Western Blotting
In a parallel experiment semapimod-treated mice and
OIR controls were sacrificed at P13, P15, or P17 and the
retinas immediately removed for Western analysis. The
disrupted tissue samples of neural retina from each
group of animals (n  8) were pooled, centrifuged at
15,000 rpm for 15 minutes to remove cell debris, and the
soluble protein extract in the supernatant was harvested
for subsequent sodium dodecyl sulfate-polyacrylamide
gel electrophoresis. The concentration of protein in the
samples was estimated using a BCA protein assay kit
(Pierce, Rockford, IL) and sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis was performed under
both denaturing and nondenaturing conditions. After
transfer to a nitrocellulose membrane (Bio-Rad, Hercules,
CA) and blocking with 5% nonfat milk the blot was
probed with anti-TNF- goat polyclonal antibody (Santa
Cruz Biotechnology Inc., Santa Cruz, CA), iNOS rabbit
polyclonal antibody (AbCam, Cambridge, UK), or -actin
rabbit polyclonal antibody (AbCam) in Tris-buffered sa-
line-Tween for 2 hours. After extensive washing in Tris-
buffered saline-Tween an anti-goat secondary antibody-
horseradish peroxidase conjugate (DAKO, AS, Glostrup,
Denmark) was added to the membrane at a dilution of
1:2500 for 45 minutes. As a loading control, -actin was
probed with a 1:5000 dilution of a monoclonal antibody
(mAb) (Sigma-Aldrich Ltd.) for 1 hour, washed as before,
and detected with an appropriate second Ab-horseradish
peroxidase conjugate (Santa Cruz Biotechnology Inc.).
Immunoreactivity was detected with Supersignal West
Pico chemiluminescent substrate (Pierce) on Hyperfilm
(Amersham Biosciences UK Ltd., Chalfont St. Giles, UK).
Band densitometry was performed using LabWorks v4.08
software on images acquired by AutoChemi system
(charge-coupled device camera and autorad transillumi-
nation) (both from UVP Inc., Upland, CA). Statistical anal-
ysis was conducted using a one-way analysis of variance
and data were considered significant at 95% (P  0.05).
Determination of Retinal Hypoxia
Treatment with Hypoxyprobe (HP) Bio-Reductive
Drug
For determination of retina hypoxia, further groups at
P13 and P17 (n 8) of hyperoxia-exposed mice (WT and
TNF-/) received an intraperitoneal injection of the
bio-reductive drug pimonidazole24 (HP; Chemicon Eu-
rope Ltd., Chandlers Ford, UK) at 60 mg/kg 3 hours
before sacrifice to assess retinal hypoxia in semapimod-
treated WT and TNF-/ animals compared to OIR
controls.
HP Immunolocalization
For this, one eye from each animal was fixed in 4%
paraformaldehyde for 4 hours and then washed exten-
sively throughout a 4-hour period after which the anterior
segment lens complexes were removed and the posterior
eye cups relaxed by placing four radial cuts from the
retinal periphery to points within 1 mm from the optic disk.
The specimens were then given an overnight soak in
96-well plates at 4°C in phosphate-buffered saline (PBS)
containing 0.5% Triton X-100 to permeabilize the tissue,
and 5% normal goat serum (Sigma-Aldrich Ltd.) to block
nonspecific binding of the primary antibody. For visual-
ization of the HP-protein adducts an anti-HP mouse
monoclonal antibody (HP-mAb; Chemicon Europe Ltd.)
or a rabbit polyclonal antibody (gift from Dr. James A.
Raleigh, University of North Carolina School of Medicine,
Chapel Hill, NC) were used at a dilution of 1:100 for 4
hours at 37°C and 100% humidity. Each immunoreagent
incubation was followed by extensive washing in the
permeabilization buffer (8 changes) throughout a fur-
ther 4 hours at 37°C and an additional block with 5%
normal goat serum for 2 hours at 37°C. A 1:500 dilution of
a goat anti-mouse polyclonal antibody labeled with Al-
exa-488 (Molecular Probes Europe BV, Leiden, The Neth-
erlands) was used for secondary detection; the staining
time and subsequent washing were as used for the pri-
mary antibody. Both retinas of two OIR mice were used
for immunocytochemical controls: two were stained with
the second antibody only and two with 5% mouse serum
(Vector Laboratories Ltd., Peterborough, UK) in place of
the primary antibody. If nuclear staining was required,
retinas were incubated in 5 nmol/L propidium iodide in
permeabilization buffer for 10 minutes at 37°C.
In nonfluorescein-dextran-perfused eyes the retinal
vasculature was visualized by reaction with biotinylated
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isolectin B4 from G. simplicifolia (Sigma-Aldrich Ltd.) at 50
ng/ml followed by streptavidin-Alexa 568 (Molecular
Probes Europe BV). Retinal flat-mounts were washed
extensively and mounted in Vectasheild (Vector Labora-
tories Ltd.). Images were acquired using an Olympus
BX60 fluorescence microscope (Olympus UK Ltd., Lon-
don, UK) fitted with a MicroRadiance confocal-scanning
laser microscope (Bio-Rad).
Quantification of HP
Unfixed neural retina of WT (semapimod-treated and
untreated) and TNF-/ mice (n  6) were dissected
and subjected to ultrasonic disruption in RIPA buffer. For
quantification of HP-protein binding, retinal samples from
P13 and P17 mice were prepared for a HP competitive
enzyme-linked immunosorbent assay (ELISA) methodol-
ogy. Briefly, 100 l of sample or standard in duplicate
were serially diluted in PBS/5% Tween 20 in a 96-well
polystyrene assay plate (Corning Inc., Corning, NY) and
incubated with 25 l of rabbit polyclonal antibody against
HP (1:3300 in PBS/5% Tween; kindly donated by Dr.
James A. Raleigh, University of North Carolina School of
Medicine, Chapel Hill, NC) for 1 hour at 37°C. The con-
tents of each well was then transferred to NUNC C96
Maxisorp plates that had been precoated with solid
phase antigen (1:5000 in carbonate buffer, pH 9.6) over-
night at 4°C and blocked with 1% gelatin for 1 hour. The
competition between solid phase and soluble antigens
proceeded for 1 hour at 37°C, after which the wells were
washed 4  5minutes with PBS/5% Tween, and 100 l of
1:2000 alkaline-phosphatase goat anti-rabbit IgG (Sig-
ma-Aldrich) was added to each well. Plates were then
washed 4  5minutes with PBS/5% Tween, and 100 l of
1 mg/ml of the alkaline-phosphatase substrate, 4-nitro-
phenyl phosphate disodium salt hexahydrate (Sigma-Al-
drich) dissolved in 10% diethanolamine buffer (pH 9.6)
was added to each well. The color development of the
subsequent reaction was measured at 405 nm every 5
minutes for 2 hours on a Safire microplate reader (Tecan
Instruments) and reaction kinetics analyzed using Magel-
lan 3 software. Sample HP-1 binding was determined by
comparison to a Lineweaver-Burk enzyme kinetic stan-
dard curve, and is expressed as a proportion of sample
protein concentration. The solid-phase antigen used in
this assay was HP, which had been reductively bound to
bovine serum albumin.25 Statistical analysis was con-
ducted using the Student’s t-test and a P value 0.05
was considered significant.
Results
Western analysis for retinal TNF- expression demon-
strated a reduction in non-OIR mice from P13 to P17
(Figure 2). On densitometric quantification of retinal ex-
tracts from OIR-controls, there was a significant increase
in TNF- expression at P15 and P17 compared to the P13
time point (P  0.05) (Figure 2). In semapimod-treated
mice subjected to OIR, there was a significant reduction
Figure 3. OIR-induced retinal ischemia: promotion of intraretinal revascu-
larization by TNF- inhibition. FITC-dextran angiograms of retinal quadrants
from OIR control animals show a complete closure of the central retinal
capillary beds (arrows) at P12 (A) (optic disk is indicated by *). B: At P17
semapimod-treated OIR mice show evidence of intraretinal revascularization
(RV). C: WT OIR (control) mice at P17 show areas of preretinal neovascu-
larization (arrows), both at the peripheral retina and optic disk (OD). D: In
H&E-stained sections there are clear neovascular complexes on the retinal
surface (arrow).
Figure 2. Semapimod inhibits TNF- in murine retina. A: Representative
Western blot analysis of TNF- and -actin in murine retina from nonhyper-
oxia-exposed mice, OIR mice, and OIR mice treated with semapimod. Data
are shown for retinal extracts from P13, P15, and P17 time periods. B:
Densitometric analysis of TNF- Western blot. Data represent the mean 
SD for n  3 independent experiments. Data are expressed as percentage
of control (room air only) mice. *, Significantly different from OIR control
(P  0.05).
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in retinal TNF- expression at both P15 and P17 when
compared to OIR controls (50%; P  0.05) (Figure 2).
When neonatal mice were returned to room air after
hyperoxia (P12) the established closure and nondevel-
opment of the central capillary beds rendered the central
retina ischemic/hypoxic (Figure 3A). A further 5 days in
room air produced some intraretinal vascular recovery
with revascularization from the perfused retinal periphery,
especially in semapimod-treated or TNF-/mice (Fig-
ure 3B). Neovascular complexes originating at the per-
fused periphery and optic disk were seen to invade the
vitreous body and proliferate on the retinal surface over-
lying the hypoxic neuropile (Figure 3, C and D). At P13,
which represents a full 24 hours of ischemic hypoxia in
the central retina, treatment with semapimod caused an
increase in the area of avascular/ischemic retina in com-
parison to OIR controls (P  0.01) (Figure 4A); a similar
trend was noted in the TNF-/ mice and reflected in
the overall level of retinal hypoxia as quantified by com-
petitive ELISA analysis of HP adducts (Figure 4B). How-
ever, by P17 the situation was reversed. Compared to
OIR controls at P17, there was a significant decrease in
area of avascular (ischemic) retina in both TNF-/
mice and WT animals treated with semapimod (P 
0.001) (Figure 5A). This was accompanied by a corre-
sponding and significant increase (P 0.001) in intrareti-
nal vascularization (normal vascularization, Figure 5B)
and a decrease in preretinal neovascularization (P 
0.01 to 0.001) (Figure 5C) in semapimod-treated and
TNF-/ mice when compared to WT OIR control ani-
mals. In all of the retinal vascular parameters analyzed,
there was no significant difference between semapimod
treatment and deletion of TNF- (Figure 5). ELISA quan-
tification of HP adducts at P17 proved unreliable because
some HP deposits in the vascular endothelial cells during
postmortem hypoxia and the large increase in the overall
quantity of retinal vessels at P17 compared to P13 meant
that this discrepancy became significant. Interpretation
of HP ELISA data at P17 was further complicated by the
Figure 4. A: TNF- modulates hyperoxia-induced retinal vascular closure.
The areas of avascular retina were quantified in retinal flat-mounts at P13.
When WT OIR mice were treated with semapimod there was an increase in
the area of avascular retina in comparison to OIR WT controls. This pattern
of avascular retina was also evident in TNF-/ mice subjected to OIR.
Data are the mean  SD for n  3 independent experiments (*, P  0.05).
B: Retinal hypoxia is increased with semapimod or absence of TNF-.
Competitive HP ELISA demonstrates increased HP immunoreactivity in reti-
nal lysates from P13 mice for both semapimod-treated mice and TNF-/
mice. Data are expressed as the mean concentration per g of total protein
(mol/L/g)  SD for n  6 (**, P  0.01; n  3 independent experiments).
Figure 5. TNF- inhibition or deletion reduces retinal neovascularization
with concomitant reduction of ischemia and promotion of normal retinal
vascularization. Quantitative analysis was performed on the entire retinal
microvasculature in flat-mounts at P17. Semapimod treatment and absence of
TNF- resulted in a significant decrease in retinal ischemia (A), an increase
in normal (intraretinal) vascularization (B), and a decrease in preretinal
neovascularization (C) when compared to WT controls. Data are the mean
SD for n  3 independent experiments. **, P  0.01; ***, P  0.001.
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fact, as noted below in immunofluorescent staining, that
the preretinal neovascular complexes provided sufficient
oxygenation to prevent the reduction of HP in the under-
lying neural retina.
Immunofluorescent localization of the hypoxia marker
pimonidazole (HP) showed deposition of protein adducts
within the nonperfused central retina distal from the tra-
versing major blood vessels (Figure 6, A and B). Inter-
estingly, no HP staining was detected in nonperfused
retina underlying preretinal neovascularization com-
plexes (Figure 6C) indicating that the underlying inner
retina was receiving significant oxygenation from the
overlying neovascularization to prevent the reductive me-
tabolism of HP and deposition of stainable drug-protein
adducts.
HP was deposited predominantly within the cytoplasm
of neurons in the ganglion cell layer (Figure 6D) reflecting
both their metabolic activity and distal location to the
nearest source of oxygen in the choroid; the stained cells
probably included both ganglion and displaced ama-
crine cells. Positive staining for HP was also detected in
some horizontally orientated cell processes in the inner
plexiform layer but not in the outer retina beyond the inner
nuclear layer (data not shown). It was of interest that HP
did not appear to deposit in the retinal astrocytes, located
between the ganglion cell layer and the internal limiting
membrane. Double immunostaining of the astrocytes for
HP and glial fibrillary acidic protein revealed no co-local-
ization (data not shown). Positive staining of the blood
vessels by the HP monoclonal Ab was initially thought to be
because of detection of mouse IgG in the blood column by
the secondary Ab as it was also present in second Ab only
controls, however, subsequent staining with a rabbit poly-
clonal Ab for HP also showed positive, although reduced,
staining in the vessels, confirming reductive metabolism of
HP because of postmortem hypoxia.
Discussion
Neovascular retinopathies collectively represent a major
cause of blindness in developed countries and are char-
acterized by hypoxia-driven angiogenesis in which new
blood vessels escape the confines of the retina and grow
on the retinal surface. It is not known why such new
vessels tend to proliferate outside the retina in preference
to infiltration of the hypoxic tissue. However, it is increas-
ingly clear that this situation is open to pharmacological
manipulations that either inhibit endogenous anti-angio-
genic factors within the ischemic tissue,26 or actively
enhance proangiogenic processes such as cell attach-
ment.27 Such treatments have the potential to encourage
therapeutic angiogenesis within the ischemic retina, re-
duce tissue hypoxia, and quench the persistent stimulus
for further pathological intravitreal neovascularization.
TNF- has been shown to be anti-angiogenic in vitro28
but proangiogenic in vivo,4,29 possibly through stimula-
tion of VEGF induction30 and enhanced expression of
cell-associated proteases.8,31,32 However, there is little
published evidence concerning the role of cytokines in
the context of hypoxia-driven angiogenesis in ischemic
retinopathy. In the present study we showed that, after an
initial delay, effective absence of TNF- (by gene ablation
or pharmacological inhibition), facilitated revasculariza-
tion of the ischemic central retina, with a concomitant
reduction in neovascular invasion of the vitreous body
during OIR. The data showed good correlation of isch-
emia and hypoxia at P13, as expressed by the relative
areas of avascular retina and deposition of the hypoxia-
sensitive drug pimonidazole (HP). Also, immunofluores-
cent staining of HP adducts confirmed that the avascular
regions of inner retina were invariably hypoxic. In the
context of the neural retina this finding has some impor-
tance: The possibility of oxygen diffusion from the under-
lying choroid and adjacent ciliary circulation means that
the terms avascular and ischemic are not necessarily
synonymous when applied to the retina. Nitroimidazoles
are excellent indicators of hypoxia with sufficient sensi-
tivity to demonstrate even physiological oxygen gradi-
ents.33 As deposition of HP becomes significant at pO2
levels 10mmHg,34 an oxygen tension not significantly
lower than what is considered physiological at the outer
plexiform layer in normal retina,35 it is reasonable to con-
clude that the neovascular complexes on the retinal sur-
face were able to oxygenate the underlying retina to at
least such a degree. This finding is of interest in that
neovascular complexes at the retinal surface are likely to
reduce the expression of vasogenic growth factors by the
underlying parenchyma. The production of VEGF in par-
ticular is mediated by hypoxia-inducible factor, the ex-
pression and stabilization of which increases in inverse
Figure 6. HP is deposited at sites of retinal hypoxia during OIR. A: At P13 HP
deposition is evident (represented by green fluorescence) in the avascular
central retina but not in the perfused peripheral retina. Vessels were visual-
ized with isolectin B4 (red fluorescence); optic disk (OD) and neovascular-
ization is apparent at the periphery (NV), but not adjacent to the major retinal
arteries (arrow). B: On higher magnification of A (represented by dashed
inset) fronds of new vessels (NV) are observed but there is little HP in the
underlying retinal neuropile. C: At P17, no HP is evident in the areas
underlying neovascularization (NV). D: High magnification of P13 retinal
flat-mounts using PI as a nuclear stain reveals high levels of HP immunore-
activity in neurons of the ganglion cell layer (arrows) within nonperfused
central retina, remote from traversing arterioles. Original magnifications:
100 (A, C); 200 (B, D).
642 Gardiner et al
AJP February 2005, Vol. 166, No. 2
proportion to tissue oxygen levels36 and it is clear that
increased perfusion of the retinal neuropile in the later
stages of OIR (P17 to P21), either by intraretinal or intra-
vitreal vascularization, is likely to reduce hypoxia, and
associated VEGF expression. Such a sequence thereby
reduces the stimulus for neovascularization with resolu-
tion of the angiogenic response. A similar natural history
ensues in untreated ischemic retinopathy in human dis-
ease but in that situation the misplaced neovascular re-
sponse and associated scar tissue lead to tractional ret-
inal detachment and vitreous hemorrhage.
It is not clear why TNF- inhibition should impair reper-
fusion of the ischemic retina in the early hypoxic stage of
OIR yet enhance it in the later neovascular phase of the
condition. However, the greater level of inner retinal isch-
emia in semapimod-treated WT and TNF-/ mice at
P13 suggests that initial hypoxia-driven vasodilatation by
surviving retinal vessels may be dependent on cytokines
or associated inflammatory mediators such as the vaso-
dilator nitric oxide. Despite such delay in the immediate
response of the retinal vasculature to hypoxia, TNF-
blockade served to facilitate intraretinal angiogenesis
and recovery of the ischemic retina; this was associated
with a concomitant reduction of intravitreal neovascular-
ization in TNF-/ and semapimod-treated WT mice at
P17. Such a switch from intravitreal neovascularization to
intraretinal angiogenesis has been previously described
by Sennlaub and colleagues26 in inducible nitric oxide
synthase (iNOS) knockout mice and because TNF- and
iNOS are co-expressed in a host of inflammatory situa-
tions it is possible that both these phenomena are linked.
Although angiogenesis in the model of ischemic retinop-
athy used in this study is driven by hypoxia-mediated
expression of VEGF12,15,37 in the absence of any signifi-
cant inflammatory infiltrate, it is clear that the nature of the
angiogenic response is under the control of inflammatory
mediators38–42 and that TNF- has an important role.
This study has correlated vascular recovery and neo-
vascularization with tissue hypoxia in ischemic retinopa-
thy and shown that preretinal neovascular complexes at
the retinal surface effectively oxygenate the underlying
retinal neuropile. The data presented also shows that
inhibition/deletion of TNF- facilitates physiological an-
giogenesis within the ischemic retina with a concomitant
reduction in pathological neovascularization of the vitre-
ous body. This emphasizes the interdependence of an-
giogenesis within these two contiguous but radically dif-
ferent tissue environments in the pathogenesis of
neovascular retinopathies and the need to account for
both when evaluating new therapeutic strategies for the
treatment of retinal neovascularization. The findings fur-
ther substantiate the possibility of redirection of the an-
giogenic stimulus for therapeutic angiogenesis in the
treatment of ischemic retinopathies.
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